Insomnia Treatment Guidelines

Efficacy and Safety of Doxylamine Succinate and Diphenhydramine

The American Academy of Sleep Medicine recommends against using diphenhydramine for treating either sleep onset or sleep maintenance insomnia due to limited efficacy data and potential for adverse effects, particularly in older adults 1, 2, 3
Diphenhydramine shows minimal efficacy for insomnia with a mean sleep latency reduction of only 8 minutes compared to placebo and minimal improvement in total sleep time of 12 minutes 1, 2
Diphenhydramine shows no improvement in sleep quality compared to placebo 1, 2

The American Academy of Sleep Medicine recommends Cognitive Behavioral Therapy for Insomnia (CBT-I) as the first-line treatment for chronic insomnia before considering pharmacological options 5
When pharmacotherapy is necessary, the American Academy of Sleep Medicine recommends short/intermediate-acting benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon) or ramelteon as first-line options 3, 6
Sedating antidepressants may be considered as third-line options, particularly when comorbid depression/anxiety exists 6

First-generation antihistamines like doxylamine and diphenhydramine are associated with significant daytime sedation and performance impairment, even without subjective awareness of these effects 4
Older adults are particularly susceptible to psychomotor impairment from these medications, with increased risk of falls and subdural hematomas 4
The American Academy of Sleep Medicine explicitly recommends against using diphenhydramine for treating insomnia due to its limited efficacy and potential for adverse effects 3

Begin with CBT-I as the foundation of treatment, and consider pharmacotherapy only if necessary 5, 4
Use the lowest effective dose for the shortest period possible, and avoid diphenhydramine and doxylamine due to limited efficacy and potential for adverse effects 1, 2, 3, 4